News
TLPH
1.190
+0.85%
0.010
Weekly Report: what happened at TLPH last week (0921-0925)?
Weekly Report · 8h ago
Talphera (TLPH) Upgraded to Buy: Here's What You Should Know
NASDAQ · 09/21 16:00
Weekly Report: what happened at TLPH last week (0914-0918)?
Weekly Report · 09/21 09:05
Weekly Report: what happened at TLPH last week (0907-0911)?
Weekly Report · 09/14 09:06
Weekly Report: what happened at TLPH last week (0831-0904)?
Weekly Report · 09/07 09:05
Weekly Report: what happened at TLPH last week (0824-0828)?
Weekly Report · 08/31 09:06
Weekly Report: what happened at TLPH last week (0817-0821)?
Weekly Report · 08/24 09:06
Talphera Earnings Call Highlights Nafamostat Momentum
TipRanks · 08/24 00:23
Weekly Report: what happened at TLPH last week (0810-0814)?
Weekly Report · 08/17 09:06
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)
TipRanks · 08/14 13:00
Talphera falls despite narrower Q2 loss, NEPHRO trial progress
Seeking Alpha · 08/13 15:51
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Talphera (TLPH) and Cognition Therapeutics (CGTX)
TipRanks · 08/13 10:30
Talphera GAAP EPS of -$0.06 beats by $0.01
Seeking Alpha · 08/12 20:10
Here are the major earnings after the close Wednesday
Seeking Alpha · 08/12 14:00
Weekly Report: what happened at TLPH last week (0803-0807)?
Weekly Report · 08/10 09:05
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
PR Newswire · 08/05 20:05
Weekly Report: what happened at TLPH last week (0727-0731)?
Weekly Report · 08/03 09:05
Weekly Report: what happened at TLPH last week (0720-0724)?
Weekly Report · 07/27 09:06
Weekly Report: what happened at TLPH last week (0713-0717)?
Weekly Report · 07/20 09:05
Weekly Report: what happened at TLPH last week (0706-0710)?
Weekly Report · 07/13 09:06
More
Webull provides a variety of real-time TLPH stock news. You can receive the latest news about Talphera Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLPH
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.